Journal of Neuroimmune Pharmacology

Scope & Guideline

Innovating Insights into Neuroimmune Mechanisms

Introduction

Welcome to the Journal of Neuroimmune Pharmacology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Journal of Neuroimmune Pharmacology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1557-1890
PublisherSPRINGER
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2006 to 2024
AbbreviationJ NEUROIMMUNE PHARM / J. Neuroimmune Pharm.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES

Aims and Scopes

The Journal of Neuroimmune Pharmacology focuses on the interplay between the nervous system and the immune system, particularly how pharmacological agents can modulate these interactions in various neurological disorders. The journal aims to publish high-quality research that advances the understanding of neuroimmune mechanisms and their implications for therapeutic strategies.
  1. Neuroimmune Mechanisms:
    Research exploring how immune responses influence neurological conditions, including neuroinflammation and neurodegeneration.
  2. Pharmacological Interventions:
    Studies evaluating the efficacy of pharmacological agents in modulating neuroimmune interactions, particularly in the context of diseases like Alzheimer's, HIV, and multiple sclerosis.
  3. Translational Research:
    Research that bridges basic science and clinical applications, focusing on how findings in neuroimmunology can lead to new therapeutic strategies.
  4. Neuroinflammation:
    Investigations into the role of inflammation in neurological disorders and how it can be targeted for therapeutic benefit.
  5. Gut-Brain Axis:
    Exploration of the interactions between gut microbiota and the central nervous system, and implications for neuroimmune health.
  6. Chronic Pain and Neuropathic Pain:
    Research into the mechanisms of chronic pain, particularly how neuroimmune processes contribute to pain syndromes.
The Journal of Neuroimmune Pharmacology is witnessing several emerging themes that reflect current scientific interests and advancements in the field. These trends indicate a dynamic landscape of research that is increasingly interdisciplinary and integrative.
  1. Microglial Function and Polarization:
    There is a rising focus on understanding microglial activation states and their polarization in response to various stimuli, particularly in neuroinflammatory conditions and neurodegenerative diseases.
  2. Neuroimmune Biomarkers:
    Research is increasingly identifying biomarkers for neuroinflammation and immune activation that can aid in diagnosing and monitoring neurological disorders.
  3. Therapeutic Targeting of the Gut-Brain Axis:
    Emerging studies are exploring how gut microbiota influence neuroinflammation and cognitive function, highlighting the therapeutic potential of modulating the gut-brain axis.
  4. Neuroinflammation in Pain Management:
    An increasing number of publications are focusing on the role of neuroinflammation in chronic pain conditions, suggesting new avenues for pain management through anti-inflammatory strategies.
  5. Crosstalk Between Neurotransmitters and Immune Signaling:
    Research is trending towards understanding how neurotransmitter systems interact with immune signaling pathways, suggesting potential pharmacological targets for treating neuroimmune disorders.
  6. Impact of COVID-19 on Neuroimmune Health:
    The COVID-19 pandemic has spurred research into the neurological effects of the virus and the associated immune responses, leading to a surge in studies examining long-term neuroimmune consequences.

Declining or Waning

While the Journal of Neuroimmune Pharmacology continues to explore a wide range of topics, some areas of research have shown a decline in emphasis over recent years. These waning themes may reflect shifts in research focus or emerging priorities in the field.
  1. Traditional Neuropharmacology:
    Research that relies solely on conventional pharmacological agents without considering the immune system's role is becoming less prominent, as the field increasingly recognizes the importance of neuroimmune interactions.
  2. Non-Inflammatory Mechanisms in Neurological Disorders:
    Studies that focus solely on non-inflammatory mechanisms in neurological diseases are declining, as the understanding of inflammation's critical role in these conditions gains traction.
  3. Single-Disease Focus:
    Research concentrating on single diseases without exploring comorbidities or the broader neuroimmune landscape is waning, as there is a growing interest in holistic approaches to neuroimmune disorders.

Similar Journals

MOLECULAR PHARMACOLOGY

Pioneering Insights in Pharmacology and Drug Development
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0026-895XFrequency: 12 issues/year

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

EXPERIMENTAL NEUROLOGY

Illuminating the Future of Neurology and Development.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4886Frequency: 12 issues/year

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

Journal of Pharmacology & Pharmacotherapeutics

Exploring Innovations in Pharmacology and Therapeutics
Publisher: SAGE PUBLICATIONS INCISSN: 0976-500XFrequency: 4 issues/year

Journal of Pharmacology & Pharmacotherapeutics is a vital academic resource published by SAGE Publications Inc., focusing on the diverse and evolving fields of pharmacology and pharmacotherapy. With an ISSN of 0976-500X and E-ISSN 0976-5018, this journal serves as a platform for rigorous research and innovative insights from 2010 to 2024, reflecting the latest advancements and challenges within the pharmacological landscape. Despite being placed in the Q4 quartile for both general pharmacology and medical pharmacology in 2023, it continues to be an essential resource for researchers, professionals, and students striving to understand the complexities of drug action, therapy optimization, and pharmaceutical sciences. The journal underscores the importance of disseminating critical findings to stimulate further research and collaborative dialogue. Although currently not open access, it can be accessed through leading academic databases, positioning itself as a significant entity in the medical and pharmacological research community.

International Immunopharmacology

Bridging Immunology and Pharmacology for Tomorrow's Therapies
Publisher: ELSEVIERISSN: 1567-5769Frequency: 12 issues/year

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

BRAIN RESEARCH BULLETIN

Connecting minds through groundbreaking neuroscience discoveries.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0361-9230Frequency: 8 issues/year

BRAIN RESEARCH BULLETIN is a leading academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, dedicated to the dissemination of high-quality research in the interdisciplinary field of neuroscience. Since its inception in 1976, this journal has served as a vital platform for researchers, professionals, and students interested in a broad spectrum of topics within neuroscience, making significant contributions to the understanding of brain function and its associated disorders. With a commendable impact factor and a current Scopus rank of #35 out of 113 in general neuroscience, the journal holds a Q2 quartile ranking, underscoring its relevance and influence in the academic community. BRAIN RESEARCH BULLETIN invites submissions of original articles, reviews, and brief communications, enhancing scholarly communication within this dynamic field. Although the journal is not open access, it ensures widespread reach and impact through various subscription models, allowing access to pivotal findings that pave the way for future research advancements. For researchers aiming to share impactful discoveries and insights within the neuroscience community, BRAIN RESEARCH BULLETIN remains an essential outlet.

LIFE SCIENCES

Pioneering research at the forefront of biochemistry and genetics.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0024-3205Frequency: 24 issues/year

LIFE SCIENCES, published by PERGAMON-ELSEVIER SCIENCE LTD, is an esteemed international journal that has been advancing the field since its inception in 1962. With an ISSN of 0024-3205 and an E-ISSN of 1879-0631, it serves as a critical forum for researchers, professionals, and students within the realms of biochemistry, genetics, molecular biology, medicine, and pharmacology. Currently ranked in the Q1 category across multiple disciplines, including a remarkable 2nd rank in General Pharmacology, Toxicology, and Pharmaceutics, the journal maintains a prestigious position in academic circles, evidenced by its high impact factor and significant percentile ranks. While LIFE SCIENCES is not an open-access journal, it remains dedicated to publishing high-quality, peer-reviewed research that pushes the boundaries of knowledge and fosters innovation. With converged research interests leading into 2024, LIFE SCIENCES continues to be a pivotal resource for the dissemination of influential findings, making it an indispensable tool for those engaged in the life sciences.

Journal of Pharmacological Sciences

Transforming research into therapeutic advancements.
Publisher: JAPANESE PHARMACOLOGICAL SOCISSN: 1347-8613Frequency: 12 issues/year

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

Current Molecular Pharmacology

Pioneering Research for Tomorrow's Therapeutics
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

NEUROMOLECULAR MEDICINE

Exploring the Intricacies of Neurological Mechanisms
Publisher: HUMANA PRESS INCISSN: 1535-1084Frequency: 4 issues/year

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Physiology and Pharmacology

Disseminating high-quality research for a healthier future.
Publisher: IRANIAN SOC PHYSIOLOGY & PHARMACOLOGYISSN: 2476-5236Frequency: 4 issues/year

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.